Valerion Therapeutics, LLC

About:

Valerion Therapeutics develops therapies for orphan genetic muscle diseases utilizing a novel antibody-based targeting system.

Website: http://valerion.com

Top Investors: KLP Enterprises

Description:

Valerion Therapeutics, LLC (formerly 4s3 Bioscience) is developing therapies for orphan genetic muscle diseases utilizing a novel antibody-based targeting system capable of enhanced intracellular delivery. Demonstrated pre-clinical in vivo data with the company’s two lead product candidates validates the potential of the 4s3 delivery platform for delivering muscle-protein fusions and treating multiple indications in the fields of muscular dystrophies and enzyme-deficiency disorders.

Total Funding Amount:

$21.2M

Estimated Revenue Range:

Less than $1M

Headquarters Location:

Medford, Massachusetts, United States

Founded Date:

2007-01-01

Contact Email:

info(AT)4s3bioscience.com

Founders:

Dustin Armstrong

Number of Employees:

1-10

Last Funding Date:

2013-05-30

IPO Status:

Private

Industries:

© 2025 bioDAO.ai